Ironwood Pharmaceuticals | IRWD - Operating Expenses


Ironwood Pharmaceuticals reported $57.33M in Operating Expenses for its fiscal quarter ending in December of 2024.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 242.88M 10.68M Sep/2025
Agios Pharmaceuticals USD 129.75M 9.76M Sep/2025
Almirall EUR 517.43M 43.18M Jun/2025
Alnylam Pharmaceuticals USD 881.04M 91.16M Sep/2025
Amarin USD 51.37M 14.6M Sep/2025
Ardelyx USD 105.66M 6.4M Sep/2025
Astellas Pharma JPY 419.91B 6.66B Sep/2025
AstraZeneca USD 16.69B 5.74B Sep/2025
Charles River Laboratories USD 3.41B 2.51B Sep/2025
Exact Sciences USD 875.74M 62.51M Sep/2025
Halozyme Therapeutics USD 136.34M 13.06M Sep/2025
Incyte USD 4.65B 3.75B Sep/2025
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
MacroGenics USD 67M 8M Sep/2025
Moderna USD 1.28B 232M Sep/2025
Myriad Genetics USD 229M 3.4M Sep/2025
Pacira USD 166.36M 4.5M Sep/2025
PTC Therapeutics USD 207.52M 6.21M Sep/2025
Sarepta Therapeutics USD 462.23M 33.28M Sep/2025
Takeda JPY 1.02T 400.98B Dec/2025
Ultragenyx Pharmaceutical USD 330.82M 56.44M Sep/2025